Q2 2026 saw improved profitability, strong cash reserves, and robust pipeline progress, with revenue rising year-over-year and operating losses narrowing sharply. Diagnostics and pharma segments both contributed to growth, while guidance for 2026 was raised.Based on Opko Health, Inc. [OPK] Q2 2026…
OPKO HEALTH, INC. reported second-quarter 2026 results with revenue of $163.6M, a narrower net loss of $8.4M versus a $148.4M loss a year earlier, and diluted loss per share of $(0.01), improving from $(0.19) in the year-ago quarter.Financial HighlightsBusiness HighlightsOriginal SEC Filing: OPKO H…
Q2 2026 saw a 4% revenue increase to $163.6M, driven by IP and equity gains, while net loss narrowed sharply to $8.4M. The oncology diagnostics divestiture and Nicoya equity deal boosted results, and cash reserves remain strong at $314.4M.Original document: Opko Health, Inc. [OPK] SEC 10-Q Quarterl…
Q2 2026 revenue grew to $163.5M, with operating and net losses narrowing significantly year-over-year. Clinical pipeline advanced with multiple Phase 1 trials, and strategic partnerships expanded, notably in China and with Entera Bio.Original document: Opko Health, Inc. [OPK] SEC 8-K Current Report…
OPK (Opko Health, Inc.) is set to announce its Q2'26 results on July 27, after the market closes. The earnings are expected to be disclosed at 4:05 PM ET (8:05 PM UTC).For Q2'26, revenue estimate is 131.23 million USD with EPS (earnings per share) anticipated at (0.08) USD. Learn more details at OP…
MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) NASDAQ:OPK, a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today announced that it will report operating and financial results for the sec…
